A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma (PCG PAN009-18)

General Information Age Group Adults Status Recruiting Protocol Number NCT02598349 Background Information The purpose of this research is to find out what effects, good and/or bad, proton radiation combined with chemotherapy and surgery (if performed) has on you and your pancreatic cancer. The goal is improved disease-free survival. This study will look at the side effects from the treatment and how the tumor responds to the combination of treatment with proton radiation. Offered At Inova Schar Cancer Institute 8081 Innovation Park Drive Fairfax, VA 22031A Department of Inova Fairfax Hospital Eligibility Information Adults over 18 years of age Biopsy proven adenocarcinoma of the pancreas that is unresectable, borderline resectable, medically inoperable, or patient refusing surgery ECOG Performance Status 0-2 within 8 weeks prior to study registration No evidence of metastatic disease, including ascites and/or peritoneal seeding No previous irradiation to the abdomen No prior surgical resection of pancreatic cancer Additional eligibility in protocol Ineligibility Information Evidence of distant metastasis; metastatic disease in the major viscera (organs); peritoneal seeding Previous irradiation to the abdomen Prior surgical resection of pancreatic cancer Previous history of invasive malignancy (except non-melanoma skin cancer and low to intermediate risk prostate cancer) unless the subject has been disease free for 5 years prior to registration Active, untreated infection Pregnant and/or breast-feeding women, or patients of child-producing potential not willing to use medically acceptable contraception while on treatment and for at least 12 months thereafter Additional ineligibility in protocol Inclusion of International Subjects Patients from outside of the United States may participate in the study. Enrollment and treatment must be completed at an approved PCG member institution Additional information can be found at: https://clinicaltrials.gov/ct2/show/ NCT02598349 Contact Information Contact Name Sangeetha Moturi Contact Phone 571-472-0343 Contact Email Send Email